looking forward to Bacitracin (Ophthalmic) Pronunciation (bas i TRAY sin) Dosage Forms Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product Ointment, Ophthalmic: Generic: 500 units/g (1 g [DSC], 3.5 g) Pharmacologic Category Antibiotic, Ophthalmic Pharmacology Inhibits bacterial cell wall synthesis by preventing transfer of mucopeptides into the growing cell wall Use: Labeled Indications Superficial ocular infections: Treatment of superficial ocular infections involving the conjunctiva or cornea due to susceptible organisms Contraindications Hypersensitivity to bacitracin or any component of the formulation Dosing: Adult Ophthalmic infection: Ophthalmic: Apply 1 to 3 times daily Dosing: Geriatric Refer to adult dosing. Dosing: Pediatric Ophthalmic infection: Children and Adolescents: Ophthalmic: Refer to adult dosing. Administration Ophthalmic: For topical ophthalmic use only; apply directly into conjunctival sac. For blepharitis, after carefully removing all scales and crusts, apply uniformly over lid margins. Avoid gross contamination of ointment during application. Storage Store at 20 C to 25 C (68 F to 77 F). Drug Interactions There are no known significant interactions. Adverse Reactions 1% to 10%: Hypersensitivity: Hypersensitivity reaction (7% [Hätinen, 1985]) Postmarketing and/or case reports (Limited to important or life-threatening): Contact dermatitis (Pichichero, 2011) Warnings/Precautions Concerns related to adverse effects: Bacterial overgrowth: Prolonged use may result in overgrowth of nonsusceptble organisms, particularly fungi; if new infection develops, initiate appropriate therapy. Hypersensitivity/anaphylaxis: Use with caution in patients who have been previously exposed to bacitracin; anaphylactic reactions have occurred on repeat exposure (Elsner, 1990; Farley, 1995). Other warnings/precautions: Appropriate use: Should not be used in deep seated ocular infections or if infection is likely to become systemic. Pregnancy Considerations Bacitracin is not absorbed systemically following ophthalmic administration (Robert, 2001). If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctual occlusion to decrease potential exposure to the fetus (Samples, 1988). Patient Education Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?) Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions. Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients. Print this page Recently Approved Lonhala Magnair Lonhala Magnair (glycopyrrolate) is a long-acting muscarinic antagonist (LAMA) bronchodilator for... Ozempic Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) analog administered once-weekly for the... Ogivri Ogivri (trastuzumab-dkst) is a HER2 / neu receptor antagonist biosimilar to Herceptin indicated for... Sublocade Sublocade (buprenorphine) is a once-monthly injectable partial opioid agonist formulation for the... More profitable
looking forward to Bacitracin (Ophthalmic) try to be
EmoticonEmoticon